The global Radiation Toxicity Treatment Market Trend was valued at US$ 3.55 Bn in 2021 and is expected to reach US$ 5.58 Bn by 2029, finds Future Market Insights (FMI) in a recent market survey.
Cancer is one of the leading causes of death around the world. The global prevalence of cancer is continuously increasing, increasing the demand for radiotherapy as a therapeutic option. Being exposed to radiations during radiotherapy causes radiation toxicity.
As per the previous decade’s trend, around 50% of patients with liver cancer, colon cancer, pancreatic cancer, and prostate cancer were treated with radiotherapy. Radiotherapy not only destroys tumor cells, but it also destroys normal and healthy cells in the proximity of the tumor. This is the primary cause of radiation toxicity in 60% of individuals who receive radiotherapy. As a result, with the rising prevalence of cancer, the number of cases of radiation toxicity is also increasing around the world.
Significant investments in nuclear energy in some countries have been increased in recent years, resulting in more nuclear facilities, which has raised the risk of individuals being exposed to radiation. The radiotherapy coverage policies and reimbursements provide easy access to radiotherapy treatments.
Download Sample Copy @ https://www.futuremarketinsights.com/reports/sample/REP-GB-10724
Increased usage of positron emission tomography (PET) and single photon emission computed tomography (SPECT) scanners in hospitals and diagnostic centers increases radiation toxicity due to gamma radiation emission, which provides a potential growth opportunity for the radiation toxicity market.
Regulatory compliances and clinical outcomes of treatment are dynamics which impact the market for radiation toxicity treatment. The market is subject to be influenced by macro, regulatory, and industrial factors. Developing radiation-drug combinations, and implementation of non-ionic radiations for therapeutic use are key market developments.
According to FMI analysis, the radiation toxicity treatment market will show a decline in H1-2022 (O) growth rate as compared H1-2021 by nearly 5 BPS. Additionally, comparison of the growth rate for the projected H1-2022 and Outlook H1-2022 period also showed a dip by nearly 10 BPS.
Acute radiation damage, distal atrophy and necrosis, and radiation injury are factors which are leading towards a reduction in the BPS value for the radiation toxicity treatment market.
Development of treatment systems that use modulated beams of photons and protons to improve cancer outcomes by irradiating cancerous tissues in ways that lead to improved control of tumors and by reducing doses to healthy tissues to reduce treatment complications are two key factors which display a progressive approach towards growth for the overall radiation toxicity treatment market.
Conversely, other market segments are expected to perform objectively and achieve lucrative growth prospects in the next half of projection period, owing to the clinical development of novel drug-radiotherapy.
2014-2021 Market Demand Outlook for Radiation Toxicity Treatment compared to 2022-2029 Forecast
Sales of radiation toxicity treatment market grew at a CAGR of 4.9% between 2014 and 2021. In 2021, the global market of radiation toxicity treatment accounts for approx. 38% of the overall toxicology drug screening market that accounts for around US$ 9.4 Bn.
Request for Customization @ https://www.futuremarketinsights.com/customization-available/REP-GB-10724
Radiation used in the treatment also damages the healthy cells present around cancer tumors in the human body, resulting into side effects such as dry mouth, mouth and gum sores, difficulty in swallowing, stiffness in the jaw, nausea, and others, after a duration ranging from days, months, to years.
For the prevention of damage to the healthy cells, radiologists and dosimetrists are focusing on using software such as treatment planning software, radiation dose management, and others for providing the right amount of radiation doses to the patients at targeted locations, without harming the healthy cells around the tumor.
With technological evolution in the field of radiation, automation is successfully implemented in radiotherapy. Radiation therapy centers are increasingly using advanced software, such as treatment planning software, for developing a treatment plan for each beamline route for estimating the direction in which the therapy system will deliver radiotherapy to a patient hence, the demand for radiation toxicity treatment will increase and will drive the market.
The radiation toxicity treatment market is expected to grow in the future, as the healthcare profession continues to evolve as a result of the need to discover newer technologies to effectively diagnose any issue.
In addition, the market’s growth is expected to be boosted by rising acceptance and quick expansion of new technologies in emerging economies throughout the forecast period. Leading companies are concentrating their efforts on the launch of new products as well as research and development.
Considering this, FMI expects the global radiation toxicity treatment to grow at a CAGR of 5.8% through 2029.
Which Factors Are Restraining the Demand for radiation toxicity treatment?
Lack of guidance regarding rare diseases such as acute radiation syndrome-specific research methodologies and identifying patients for study specially including very impaired or minimally impaired patients in research remains a challenge.
There also exist various legal and ethical issues to find adequate sample size for clinical research. Selecting appropriate outcomes and their measurement is difficult due to heterogeneity in treatment and effect of various diseases in patients due to absence of validated outcome. Also, lack of disease knowledge and diversity in terms of epidemiology, diagnosis, prognosis and treatment affects the clinical trial design and planning.
In cases of rare diseases such as acute radiation syndrome, the patient–physician relationship may not fit with the traditional assumptions of medical care. The lack of disease-related expertise among healthcare professionals and psychological challenges associated with the diagnosis of an incurable disease may lead to improper treatment. Due to poor knowledge of rare diseases and limited therapeutic options of treatments, physicians may not act as competent technical experts who provide relevant information to patients.
To avoid this, disease specialist should be trained to deal with patients with rare diseases and they must learn to cope with assertive and well-informed expert patients. Educational associations and institutions in healthcare should encourage physicians to practice and improve their skills in this area.
This can prove to be a major restraining factor for the product segment of the radiation toxicity treatment market.
Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/REP-GB-10724
What is the Impact of the COVID-19 Crisis on the Radiation toxicity treatment Market?
The radiotherapy market is growing slowly as a result of the coronavirus pandemic, since the healthcare community’s focus has changed from chronic diseases in limiting the transmission of COVID-19. As a result, a number of cancer-specialty hospitals have closed or been converted to COVID care centers. Furthermore, the import and export of radiotherapy systems have been severely hampered by the uncertain supply chain.
However in 2021, as the recovery began, some hospitals reopened their cancer units, which increased the number of radiotherapy treatments. After the second wave, a large number of population got treated for radiotherapy which augmented the growth of radiation toxicity treatment market.
Country-wise Insights
What Makes the U.S. the Largest Market for radiation toxicity treatment?
In 2021, the U.S. dominated the North American market, with more over 91% of the market share. The United States has the largest market for radiation toxicity treatment. The market is driven by factors such as rising cancer incidence and mortality, the replacement of older therapies with newer ones, and the provision of reimbursements for radiation toxicity therapy, the U.S is expected to reflect similar market trends over the projection timeframe.
Furthermore, in the United States, the implementation of safety rules and policies, improved treatment outcomes of radiation toxicity therapy, and significant investments by key manufacturers in product development and distribution are boosting radiation toxicity treatment market growth.
Why is Germany Considered a More Lucrative Market for Radiation Toxicity Treatment in Europe?
Germany dominated the European radiation toxicity treatment market and accounted for approx. 20.6% of market share in 2021, owing to increased use of PET and single-photon emission computed tomography scanning machines across various diagnostic centers. Furthermore, favorable health coverage policies and stringent regulations have boosted the market growth in the region.
While Europe is identified as a lucrative market, stakeholders are particularly eying the profits in East and South Asia. These regional markets are turning attractive with the increasing per capita healthcare expenditure and multiple government programs for integrated healthcare systems.
What are the Factors Fueling the Demand for Radiation Toxicity Treatment in China?
The radiation toxicity treatment market in China is projected to grow at a 10.4% CAGR in East Asia throughout the forecast period. Rising awareness about advanced radiation toxicity treatments, as well as improving healthcare infrastructure, are expected to fuel the growth of the China radiation toxicity treatment market throughout the forecast period.
Furthermore, China’s radiation toxicity treatment market is expected to rise at a faster rate by 2029 as a result of a strong focus on research and development in the region.
What Makes India an Emerging Market for Radiation Toxicity Treatment?
India is an emerging market for radiation toxicity treatment and account for the largest share for more than 48% in South Asia radiation toxicity treatment market due to improving healthcare infrastructure, large patient base for target diseases, and growing presence of leading market players in the region to grab advantage of the rising opportunities given in India. These are the main drivers of radiation toxicity treatment market growth in this region.
Category-wise Insights
Why Colony Stimulating Factors accounts for the highest share by Product?
Colony stimulating factors is the leading segment and expected to gain more than 78% of revenue share in 2021 owing to the increasing adoption of colony-stimulating factors (CSFs). The management of febrile neutropenia in cancer patients has become increasingly important as chemotherapy doses have been increased and the variety of available treatment lines has grown. Colony-stimulating factors (CSFs) are growth hormones that prevent chemotherapy-induced neutropenia. They include granulocyte-colony stimulating factors (G-CSF) and granulocyte macrophage-colony stimulating factors (GM-CSF). They are utilized in frail patients undergoing chemotherapy and patients undergoing highly haematotoxic programs.
Why do Acute Radiation Syndrome Contribute the Highest Market Share by Indication?
Acute radiation syndrome are caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time. The acute radiation syndrome segment by indication is projected to account for 87.8% of the total market share in 2021 as acute radiation syndrome is highly progressive by nature and can effects the patients in less than 24 hours of exposure to radiation.
Why Ionizing Radiation Contribute to the highest market share by Type of Radiation?
Representing a whopping 89.6% share in global market in 2021, ionizing radiation remains the highly preferred radiation toxicity treatment, particularly in developed countries. On the other side, it also continues to witness growing traction within developing regional markets. Under ionizing radiation, gamma radiation method accounts for over 55.8% share, while alpha and beta radiation methods are observing significant adoption.
Which End User will be Most Preferred?
Hospital segment accounts for the highest share of over 88% in 2021 by end user due to increasing adoption and increasing footfalls to seek effective radiation toxicity treatment at hospitals, availability of advance devices and presence of qualified medical personnel in the hospital.
Competitive Landscape
The global radiation toxicity treatment market is highly consolidated. Leading players of the radiation toxicity treatment market are also emphasizing on collaboration with distributor or local manufacturer to enhance their distribution channel in emerging economies.
For instance, In September 2020, the AI-Rad Companion Organs RT, the latest AI-Rad Companion artificial intelligence-based software assistant from Siemens Healthineers, has received FDA approval. As part of the radiation therapy planning workflow, AI-Rad Companion Organs RT uses deep-learning AI algorithms to autonomously outline organs at risk (OARs) on computed tomography (CT) images, facilitating precision medicine.
In May 2018, Partner Therapeutics signed distribution agreement with Tanner Pharma Group for the distribution of Leukine in the areas outside the U.S. and Canada.
In January 2017, Jubilant Life Sciences Limited signed a long-term contract with distribution networks in the US for supply of products used for diagnostic and therapeutic products with Montreal Canada (JDI).
Radiation toxicity treatment Market by Category
By Product :
- Colony Stimulating Factors
- Potassium Iodide
- Prussian Blue
- Diethylenetriamine Pentaacetic Acid
- Others
By Indication :
- Acute Radiation Syndrome
- Bone Marrow Syndrome (Hematopoietic)
- Gastrointestinal Syndrome (GI)
- Cardiovascular (CV)
- Chronic Radiation Syndrome
By Radiation Type :
- Ionizing Radiation
- Alpha Radiation
- Beta Radiation
- Gamma Radiation
- Non-ionizing Radiation
By End-User :
- Hospitals
- Government Hospitals
- Private Hospitals
- Research & Academic Institutes
- Government Research and Academic Institutes
- Private Research and Academic Institutes
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa (MEA)
Top Related Reports Healthcare Market Insights
https://www.directoryrail.com/preview-directory/
https://healthcarefmi.blogspot.com/2022/09/downstream-processing-market-report.html
https://healthandfitness901316.blogspot.com/2022/09/downstream-processing-market-creating.html
https://myjoye.com/blogs/773/3205/downstream-processing-market-potential-growth-share-demand-an
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs